Literature DB >> 30664810

Characteristics and prognostic significance of profiling the peripheral blood T-cell receptor repertoire in patients with advanced lung cancer.

Yang-Yang Liu1, Qi-Fan Yang1, Jing-Song Yang1, Ru-Bo Cao1, Jin-Yan Liang1, Yu-Ting Liu1, Yu-Lan Zeng1, Si Chen2, Xue-Feng Xia2, Kai Zhang1, Li Liu1.   

Abstract

Lung cancer is one of the greatest threats to human health, and is initially detected and attacked by the immune system through tumor-reactive T cells. The aim of this study was to determine the basic characteristics and clinical significance of the peripheral blood T-cell receptor (TCR) repertoire in patients with advanced lung cancer. To comprehensively profile the TCR repertoire, high-throughput sequencing was used to identify hypervariable rearrangements of complementarity determining region 3 (CDR3) of the TCR β chain in peripheral blood samples from 64 advanced lung cancer patients and 31 healthy controls. We found that the TCR repertoire differed substantially between lung cancer patients and healthy controls in terms of CDR3 clonotype, diversity, V/J segment usage, and sequence. Specifically, baseline diversity correlated with several clinical characteristics, and high diversity reflected a better immune status. Dynamic detection of the TCR repertoire during anticancer treatment was useful for prognosis. Both increased diversity and high overlap rate between the pre- and post-treatment TCR repertoires indicated clinical benefit. Combination of the diversity and overlap rate was used to categorize patients into immune improved or immune worsened groups and demonstrated enhanced prognostic significance. In conclusion, TCR repertoire analysis served as a useful indicator of disease development and prognosis in advanced lung cancer and may be utilized to direct future immunotherapy.
© 2019 UICC.

Entities:  

Keywords:  T-cell receptor repertoire; high-throughput sequencing; immunotherapy; lung cancer; prognosis

Year:  2019        PMID: 30664810     DOI: 10.1002/ijc.32145

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

1.  Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor.

Authors:  S Ji; J Li; L Chang; C Zhao; R Jia; Z Tan; R Liu; Y Zhang; Y Li; G Yin; Y Guan; X Xia; X Yi; J Xu
Journal:  Clin Transl Oncol       Date:  2021-02-13       Impact factor: 3.405

2.  Characteristics, dynamic changes, and prognostic significance of TCR repertoire profiling in patients with renal cell carcinoma.

Authors:  Liping Guo; Xingang Bi; Yajian Li; Li Wen; Wen Zhang; Weixing Jiang; JianHui Ma; Lin Feng; Kaitai Zhang; Jianzhong Shou
Journal:  J Pathol       Date:  2020-03-24       Impact factor: 7.996

Review 3.  Intratumoral Versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One?

Authors:  Marta Gascón; Dolores Isla; Mara Cruellas; Eva M Gálvez; Rodrigo Lastra; Maitane Ocáriz; José Ramón Paño; Ariel Ramírez; Andrea Sesma; Irene Torres-Ramón; Alfonso Yubero; Julián Pardo; Luis Martínez-Lostao
Journal:  Cells       Date:  2020-06-22       Impact factor: 6.600

4.  Pegylated recombinant human granulocyte colony-stimulating factor regulates the immune status of patients with small cell lung cancer.

Authors:  Jing Sun; Hua Bai; Zhijie Wang; Jianchun Duan; Jin Li; Ruimin Guo; Jie Wang
Journal:  Thorac Cancer       Date:  2020-02-05       Impact factor: 3.500

5.  A comprehensive model based on temporal dynamics of peripheral T cell repertoire for predicting post-treatment distant metastasis of nasopharyngeal carcinoma.

Authors:  Yajing Zhang; Yujie Zhu; Jiaqi Wang; Yi Xu; Zekun Wang; Yang Liu; Xuebing Di; Lin Feng; Ye Zhang
Journal:  Cancer Immunol Immunother       Date:  2021-08-03       Impact factor: 6.968

6.  Development and validation of an individualized immune prognostic model in stage I-III lung squamous cell carcinoma.

Authors:  Qi-Fan Yang; Di Wu; Jian Wang; Li Ba; Chen Tian; Yu-Ting Liu; Yue Hu; Li Liu
Journal:  Sci Rep       Date:  2021-06-16       Impact factor: 4.379

7.  Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1.

Authors:  Di Wu; Yangyang Liu; Xiaoting Li; Yiying Liu; Qifan Yang; Yuting Liu; Jingjing Wu; Chen Tian; Yulan Zeng; Zhikun Zhao; Yajie Xiao; Feifei Gu; Kai Zhang; Yue Hu; Li Liu
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561

8.  High-Throughput Sequencing-Based Analysis of T Cell Repertoire in Lupus Nephritis.

Authors:  Xiaolan Ye; Zhe Wang; Qiang Ye; Jing Zhang; Ping Huang; Jingying Song; Yiwen Li; Hongjuan Zhang; Feifeng Song; Zixue Xuan; Kejian Wang
Journal:  Front Immunol       Date:  2020-08-06       Impact factor: 7.561

9.  Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study.

Authors:  Chang Lu; Xiao-Rong Dong; Jun Zhao; Xu-Chao Zhang; Hua-Jun Chen; Qing Zhou; Hai-Yan Tu; Xing-Hao Ai; Xiao-Feng Chen; Gai-Li An; Jun Bai; Jin-Lu Shan; Yi-Na Wang; Shuan-Ying Yang; Xiang Liu; Wu Zhuang; Hui-Ta Wu; Bo Zhu; Xue-Feng Xia; Rong-Rong Chen; De-Jian Gu; Hua-Min Xu; Yi-Long Wu; Jin-Ji Yang
Journal:  J Hematol Oncol       Date:  2020-04-15       Impact factor: 17.388

10.  The Landscape and Prognosis Potential of the T-Cell Repertoire in Membranous Nephropathy.

Authors:  Yu Zhang; Yabin Jin; Zhanwen Guan; Huishi Li; Zuhui Su; Chao Xie; Xiangping Chen; Xiaofen Liu; Yingming Pan; Peiyi Ye; Lifang Zhang; Yaozhong Kong; Wei Luo
Journal:  Front Immunol       Date:  2020-03-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.